Teva Pharma (NYSE: TEVA) announced new data from the open-label Phase IIIb GLatiramer Acetate low frequenCy safety and patIent ExpeRience ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE